Thor Halfdanarson talks about the multidisciplinary care approach to treating patients with neuroendocrine tumors (NETs), imaging techniques for initial staging, restaging and monitoring the effectiveness of treatment in NET patients, the variations in the treatment guidelines for NETs between Europe and the USA and the main takeaways from ENETS 2024. 

Wouter de Herder explains the critical role of endocrinology in managing patients with neuroendocrine neoplasms, the principles of somatostatin analog therapy and identifies the groups of neuroendocrine tumor (NET) patients who benefit most from it, the recommended second-line treatment for patients with advanced, unresectable, or metastasized gastroentero-pancreatic NET after recurrence with somatostatin analogs, and the main highlights from ENETS 2024.

Julien Hadoux describes various ways to improve the early and accurate diagnosis and treatment of patients with neuroendocrine tumors (NETs), the present and future aspects of molecular profiling in the management of NETs, the use of radiopharmaceutical therapy (RPT) compared to other systemic targeted therapies in the treatment sequence of patients with NETs, and the main highlights from ENETS 2024.